臨床研究等提出・公開システム

Clinical Effects of Ubiquinol (Reduced Coenzyme Q10) for Dementia: Additional Analysis

CoQ10 for Dementia: Additional Analysis

Abe Satoshi

Shimane University Hospital

89-1 Enya-cho, Izumo City, Shimane Prefecture

sabe@med.shimane-u.ac.jp

Abe Satoshi

Shimane University Hospital

89-1 Enya-cho, Izumo City, Shimane Prefecture

+81-853202198

sabe@med.shimane-u.ac.jp

Not Recruiting

Dec. 25, 2024

Observational

Any of the following five types of dementia patients,
Alzheimer's disease dementia
Vascular dementia
Dementia with Lewy bodies
Frontotemporal dementia

1) Has a comorbid metabolic disorder (e.g., hypothyroidism, vitamin B12 deficiency).
2) Has a history of head trauma.
3) Exhibits symptoms of delirium caused by medication.
4) Is dependent on alcohol.
5) Has comorbid depression being treated with antidepressants.
6) Is receiving treatment with antipsychotic medications for psychiatric symptoms (e.g., confusion, hallucinations, delusions, or abnormal behavior).
7) Has comorbid schizophrenia, mania, severe cardiac disease, or liver disease.
8) Has impaired renal function with a creatinine clearance (Ccr) of 20 ml/min or less.
9) Is undergoing treatment for malignant tumors.
10) Is deemed unsuitable for participation in this study by the principal investigator.

Dementia

The subjects will be stratified based on hippocampal atrophy levels into two groups: less than 2.00 and less than 1.50. Neuropsychological tests (MMSE, Hasegawa Dementia Scale, Motivation Score, Self-Rating Depression Scale, Frontal Lobe Function Test, and ADAS-Jcog) will be compared before and 12 months after administration using the Wilcoxon rank-sum test.

+81-853-20-2515

Oct. 09, 2024

none